About this trial

This clinical study evaluates whether a supervised, multimodal therapeutic exercise program started before chemotherapy and continued during treatment can improve treatment outcomes in patients aged 35 to 65 years with breast, lung, or colon cancer.

The study hypothesis is that participation in this exercise program improves tolerance to chemotherapy, allowing patients to receive more than 85% of the planned relative dose intensity. In addition, the program is expected to enhance treatment effectiveness by increasing the rate of complete radiological response.

The main objective of the study is to assess the effectiveness of a supervised, multimodal therapeutic exercise program performed before and during chemotherapy in improving both treatment tolerance and treatment efficacy in patients with breast, lung, and colon cancer.

Eligibility criteria

Qualifiers

Women and men aged 35 to 65 years

Diagnosed with stage II, III, or IV breast, lung, or colon cancer

Scheduled to start neoadjuvant chemotherapy

Able and willing to provide written informed consent

Disqualifiers

Musculoskeletal or neurological disorders that prevent proper execution of the exercises

Uncontrolled infections or symptoms

Comorbidities such as chronic obstructive pulmonary disease (COPD), respiratory failure, or recent cardiovascular events within the past 6 months

Body mass index (BMI) over 35

Trial design

Treatments tested in this trial

  • PREDU Exercise Program
  • Recommendation Exercise Program

Treatment groups

70 Participants
are divided into 2 treatment groups

Locations

3
Consorci Hospitalari de Vic08500, VicBarcelona, Spain
Facultat de Ciències de la Salut i del Benestar de la Universitat de Vic (UVIC-UCC) Universitat de Vic- Universitat Central de Catalunya08500, VicBarcelona, Spain
Hospital Universitari de la Santa Creu08500, VicBarcelona, Spain

Sponsors and collaborators

University of Vic - Central University of Catalonia

Lead sponsor

Col·legi Fisioterapeutes de Catalunya

Collaborator